Acute kidney failure

1. SGLT2 inhibitors lower the risk of acute kidney failure in humans (OR 0.86, 95% CI 0.79-0.94).

   “SGLT2i versus non-SGLT2i were associated with reduced risks of ARF (OR 0.86, 95% CI 0.79-0.94)”

   Review

   Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis

   Medical sciences (Basel, Switzerland)·Mar 20, 2026

More on SGLT2 inhibitors

1. GLP-1 receptor agonists are linked with a lower risk of acute kidney failure in patients with MASLD, hyperlipidemia, and heart failure (HR 0.757).

   “acute kidney failure (HR 0.757; 95% CI 0.757; p < 0.001)”

   Humansin patients with MASLD, hyperlipidemia, and heart failure5-year

   SAT-669 Impact of GLP-1 agonist in patients with heart failure and dyslipidemia affected by Metabolic Dysfunction-Associated Steatotic Liver Disease: A prospective case control study

   ENDO 2025 abstract·Oct 22, 2025

More on GLP-1 receptor agonists

1. Acute kidney failure is linked with a higher risk of mortality in humans (postoperative) (OR 4.58, 95% CI [4.09, 5.13]).

   “acute renal failure (OR: 4.58 95% CI [4.09, 5.13], P < 0.001), pneumonia (95% CI [2.72, 3.83], P < 0.001), and myocardial infarctions (OR: 2.65, 95% CI [1.80, 3.92], P < 0.001) increased likelihood of death after undergoing HHA.”

   Humanspostoperative

   Factors that influence the mortality of patients following hip hemiarthroplasty

   Arthroplasty (London, England)·Jun 7, 2024